Relatlimab (BMS-986016, Opdualag, Bristol-Myers Squibb Company), a first-in-class anti-LAG-3 blocking antibody, represents the third approval of ICB-based therapy for patients with cancer. The gene discussed is LAG3; the disease is cancer.